Source: http://globenewswire.com/
Copenhagen, 9 December 2015 – Zealand informs that its acting Senior Vice President of Research, Keld Fosgerau presented at the New York Academy of Sciences’ (NYAS) GLP-1 Treatment for Diabetes and Beyond meeting yesterday in New York.
The New York Academy of Sciences is one of the oldest and most prestigious scientific membership organizations in the US, with over 20,000 members from around the world. The GLP-1 Treatment for Diabetes and Beyond meeting highlighted innovative scientific approaches to GLP-1 based new therapies in the preclinical and clinical arena with a focus on human genetics, novel cellular and molecular mechanisms for insulin secretion and weight loss, new indications and new opportunities for drug development.
In his presentation, Keld Fosgerau discussed various approaches applied by Zealand in the creation of second generation GLP-1 based therapies, and how these can help address unmet medical needs in the field of Type 2 diabetes and obesity. He showcased the company’s leading expertise in the synthesis of novel dual acting peptides and in developing those peptides to create compelling new medicines. The Zealand peptides that were presented include ZP2929, a glucagon/GLP-1 dual agonist in clinical Phase I development for improved weight management in diabetes, a preclinical GIP/GLP-1 dual agonist for greater therapeutic index with reduced risk of hypoglycemia, and a preclinical gastrin/GLP-1 dual agonist for the prevention of beta cell decline.
Read more: http://globenewswire.com/news-release/2015/12/09/794000/0/en/Zealand-presented-on-its-dual-acting-peptides-at-the-New-York-Academy-of-Sciences-meeting-GLP-1-Treatment-for-Diabetes-and-Beyond.html